IDEXX LaboratoriesFRA:IX1 -0.82%96 3-Year ROIIC % is 140.66 as of Dec. 2025, which is 150% above its 10-year median of 56.19. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €565.16 (Modestly Undervalued). Among 203 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 83.74% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
IDEXX Laboratories's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 140.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for IDEXX Laboratories's 3-Year ROIIC % or its related term are showing as below:
FRA:IX1's 3-Year ROIIC % is ranked better than 83.74% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs FRA:IX1: 140.66
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
IDEXX Laboratories 3-Year ROIIC % Related Terms
IDEXX Laboratories 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IX1 vs A, NTRA, WAT: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
IDEXX Laboratories (FRA:IX1) has a 3-Year ROIIC % of 140.66 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on IDEXX Laboratories and its competitors. This is 150% above median its historical median of 56.19. Over the past decade, IDEXX Laboratories' 3-Year ROIIC % has ranged from 10.81 to 421.22. According to the industry distribution chart, IDEXX Laboratories ranks #33 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 16.3%.
Is IDEXX Laboratories' 3-Year ROIIC % too high?
IDEXX Laboratories' current 3-Year ROIIC % of 140.66 is 150% above median its 10-year median of 56.19. Over the past 10 years, this metric has ranged from a low of 10.81 to a high of 421.22. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. IDEXX Laboratories' value of 140.66 is 63836.4% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #33 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' 3-Year ROIIC % compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #33 out of 203 companies for 3-Year ROIIC %. This places IDEXX Laboratories in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. IDEXX Laboratories' value of 140.66 is 63836.4% above this benchmark. Historically, IDEXX Laboratories' own 3-Year ROIIC % has ranged from 10.81 to 421.22 over the past decade. While the company's 10-year median is 56.19 vs. the industry median of 0.22, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current 3-Year ROIIC % of 140.66 is 63836.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current 3-Year ROIIC % is 140.66, which is 150% above median its own 10-year median of 56.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €565.16, compared to a current price of €496.30 — trading 12.2% below its estimated fair value. The current 3-Year ROIIC % is 140.66, which is 150% above median its 10-year median of 56.19 and 63836.4% above the Medical Diagnostics & Research industry median of 0.22. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current 3-Year ROIIC % is 140.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €496.30 is trading 12.2% below its estimated GF Value™ of €565.16.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
3-Year ROIIC %: 140.66 (150% above median its 10-year median of 56.19)
GF Value™: €565.16 vs. price of €496.30 (12.2% below fair value)
Industry Position: 63836.4% above the Medical Diagnostics & Research median (#33 of 203)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
